![Akebia Therapeutics, Inc. logo](/logos/AKBA.webp)
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Overview | Financials
Company Name | Akebia Therapeutics, Inc. |
Symbol | AKBA |
Currency | USD |
Price | 1.35 |
Market Cap | 283,888,800 |
Dividend Yield | 0% |
52-week-range | 0.78 - 2.48 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. John P. Butler MBA |
Website | https://www.akebia.com |
An error occurred while fetching data.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD